The Cooccurrence of Obesity, Osteoporosis, and Sarcopenia in the Ovariectomized Rat: A Study for Modeling Osteosarcopenic Obesity in Rodents

Zahra Ezzat-Zadeh,1 Jeong-Su Kim,1,2 P. Bryant Chase,3 and Bahram H. Arjmandi1,2

1Department of Nutrition, Food, and Exercise Sciences, Florida State University, Tallahassee, FL, USA
2Center for Advancing Exercise and Nutrition Research on Aging (CAENRA), College of Human Sciences, Florida State University, Tallahassee, FL 32306, USA
3Department of Biological Science, Florida State University, Tallahassee, FL, USA

Correspondence should be addressed to Bahram H. Arjmandi; barjmandi@fsu.edu

Received 19 December 2016; Revised 19 March 2017; Accepted 28 March 2017; Published 1 June 2017

1. Introduction

Obesity, osteoporosis, and sarcopenia are three disease conditions that may occur due to age-related gradual alterations in body composition [1, 2]. Excess fat mass has been suggested as a risk factor for the gradual decline in muscle mass and the combination of both conditions has termed sarcopenic obesity [1]. Interestingly, in spite of the traditional belief that obesity was protective against osteoporosis, a more recent, growing body of evidence indicates that fat mass is negatively correlated with bone mass, suggesting that excess body fat has deleterious effects on bone [3, 4].

In women and certain animal models such as rat, estrogen is considered a major regulator of adipose tissue development and its deposition [5–9]. In addition to the direct role of estrogen on adipose tissue [6–8], it may also indirectly affect adiposity via regulation of food intake and energy expenditure by affecting hypothalamus functions [5, 9]. Moreover, ovarian hormone deficiency often not only is associated with an increase in fat mass, but also is linked to an accelerated loss of bone mass and development of osteoporosis [2, 3].

While the effect of estrogen on bone is better understood, its effect on other tissues including skeletal muscle is poorly understood and needs further investigation. Available findings suggest both direct and indirect roles for estrogen in muscle protein synthesis or maintaining lean tissues in both human and rodents [10, 11]. However, there is disagreement in available literature related to the effects of estrogen on skeletal...
muscle mass. Declined, increased, and maintained skeletal muscle mass has been reported following ovarian hormone deficiency and administration of estrogen, making it difficult to interpret the role of estrogen in the progressive decline of muscle mass which is clinically known as sarcopenia [12–15]. Differences in energy intake and expenditure—two main factors that affect body weight and that vary as a consequence of ovarian hormone deficiency—may partially explain discrepancies among previous findings. Additionally, the effects of ovarian hormone may be age specific and impact the role of estrogen manipulation on lean mass in growing versus mature animals [13, 14]. The duration of the estrogen deficiency [16] and specific metabolic alterations following ovariectomy in mice and rats could also be reasons of these inconstancies in the available literature [17]. It is likely that ovarian hormone deficiency results in an increased adiposity in the face of bone and muscle loss due to the adverse effect on osteoblastogenesis and myogenesis [11, 18]. These unfavorable changes in body composition may interact negatively to predispose women with low levels of ovarian hormone to impaired physical function and age-related chronic disease.

The cooccurrence of obesity, osteoporosis, and sarcopenia—three diseases that occur with advancing age and which may be affected by fluctuations in ovarian hormone production or its deficiency—has not been investigated in females while controlling for energy intake and expenditure. This study addresses two important questions: (1) do these three age-related disease conditions cooccur in females with low levels of ovarian hormone? (2) How the presence or absence of estradiol (E2), the most biologically active form of estrogen, affects muscle, bone, and fat mass in an experimental model without the confounding effects of chronological aging or genetic background?

To investigate these issues, we used Sprague-Dawley (SD) rats that were 5 or 10 months old at the beginning of the study to model pre- and postmenopausal women, respectively. Using these two age groups, we were able to compare the impact of estrogen deficiency along with advancing age without any sign and complexity of chronological aging that negatively affects body composition. We hypothesized that ovarian hormone deficiency slows resting metabolic rate and energy expenditure resulting in an increased adiposity and a body weight (BW) gain while exerting catabolic effects on lean mass, including bone mass, in both young and old experimental categories. Furthermore, we postulated that this hypothesis was independent of age. To test this hypothesis, we controlled the effects of ovarian hormone deficiency on food intake by pair-feeding all of our ovariectomized (ovx) animals to the mean food intake of sham-operated rats. We also measured changes in physical activity in response to the interventions. The study was concluded once significant loss of whole body bone mineral density (BMD) was observed. We also measured bone mineral content (BMC) of whole body, tibia, and 4th lumbar vertebra and their microstructural properties. We examined sarcopenia by measuring lean and skeletal muscle mass and adjusting the values of skeletal muscle mass by weight as the most recommended diagnostic approach to determine presarcopenia, according to the European Working Group on Sarcopenia in Older People (EWGSOP). For our investigation we selected two hindlimb skeletal muscles: the soleus (SOL) that is mostly comprised of slow-twitch muscle fibers (type I) and the gastrocnemius (GAS) that is mostly comprised of fast-twitch muscle fibers (type II). The combined muscle mass of these two skeletal muscles that either are attached (SOL) or span the tibia (GAS) was used in computing the ratio of tibial BMC to muscle mass (MM). Although there are a number of studies that have evaluated the effects of ovarian hormone deficiency on body weight, fat, muscle, and bone status, to our knowledge this is the first study that addresses osteosarcopenic obesity in experimental model and evaluates the effects of the presence or absence of estradiol on these components of body composition, while simultaneously controlling the food intake and measuring physical activity in two different aged cohorts of rats.

2. Methods

2.1. Animals and Diet. Animal protocol was approved by the Institutional Animal Care and Use Committee at Florida State University. A total of thirty-six (n = 36) 5- and 10-month-old female SD rats were divided into sham, ovariectomized (ovx), and ovx + E2 (immediately after surgery 10 μg/kg BW 17β-estradiol was injected subcutaneously twice per week) in each age group (n = 6 per treatment group). During the study period animals were pair-fed to the mean food intake of the sham with a semipurified control diet (AIN-93M) and weighed weekly until the occurrence of significant bone loss in ovx rats, which was after 3.5 months (age 8.5 months) for young and after 5 months (age 15 months) for older animals. Younger and older ovx + E2 groups received estradiol for the full duration of the study (3.5 months or 5 months, resp.). Rats were provided with free access to continuous voluntary running wheels in their individual cages for 24 hours, within 24 to 48 hours after E2 injection, one week before sacrifice. These running wheels were connected to a distance counter to measure animals’ voluntary running activity.

2.2. Tissue Collection. At the termination of the study, animals were anesthetized with ketamine/xylazine (100 mg/5 mg/kg BW) and bled from their abdominal aortas. Tissues, including bone, muscle, liver, heart, and uterus, were harvested. An incision through the skin from the medial side of the thigh to the abdomen was made. The skin was then reflected to expose the muscles of the lower leg. An incision was made along the white facial line demarcating lateral aspects of the lower leg, from the ankle to 3–5 mm proximal to the ankle. GAS and SOL muscles from hindlimb were isolated from the distal end using forceps and scissors and weighed. Bone specimens including vertebrae and tibiae were collected, cleaned of adhering tissues, and stored at −20°C for further analysis. Additionally, in order to confirm the success of ovariectomy, atrophied uterus was removed, nicked, and weighed.

2.3. Body Composition and Bone Microstructural Properties. Lean mass and fat mass, whole body, and vertebral and
tibial BMD and BMC were assessed using dual-energy X-ray absorptiometry (DXA) (Hologic Inc., Bedford, MA, USA) one week prior to removal of the ovaries (baseline) and again two weeks prior to the end of study (final) after rats were anesthetized with ketamine/xylazine (100 mg/5 mg/kg BW). Microarchitectural properties of the right tibia and 4th lumbar vertebra were assessed using a μCT 35 scanner (Scanco Medical, Brüttisellen, Switzerland). Bone and muscle specimens were frozen at −20°C for further examination in a blind manner. Tibia was scanned at the volume of interest (VOI) that was twenty-five slices away from the proximal growth plate in the distal direction (16 μm/slice) to 125 slices. The VOI for lumbar vertebra was twenty-five slices away from the growth plate at each end of the vertebral body and was scanned from the cephalic to the caudal growth plate, resulting in a total of slices. Both bone specimens were scanned at an isotropic voxel resolution of 22 μm3 using a 1024 × 1024 matrix. The integration time per projection was 70 ms and rotational step was 0.36° with a total acquisition time of 150 min per sample. The scanned VOI resulted in a total of 350 and 530 images for tibia and lumbar vertebra, respectively. Morphometric parameters calculated by scanning the VOI included bone volume over total volume (BV/TV), trabecular number (Tb. N), separation (Tb. Sp.), thickness (Tb. Th.), structure model index (SMI), and connectivity density (Conn. D). The obtained 3D microarchitecture allowed visualization of these morphometric measurements.

2.4. Blood Parameters. Blood samples were centrifuged (4°C) at 1500g for 15 minutes. Serum samples were separated, aliquoted, and stored at −20°C for analyses of 17β-estradiol and two of the most widely accepted markers of bone turnover for rats, namely, C-telopeptides of type I collagen (CTX) and bone specific alkaline phosphatase (B-ALP) [19]. These measurements were performed using enzyme linked immunoassay (ELISA) kits from TSZ ELISA (Framingham, MA, USA) and Immunodiagnostics Systems Inc. (Fountain Hills, AZ, USA), respectively, following the manufacturer’s protocols.

2.5. Statistics. Power calculation: powers for detecting differences were calculated based on a range of possible decreases in BMD of ovx rats when compared to sham-operated rats. The range of possible increases was set beginning at 1% and increased by 1.0% increments to 8%. The power was calculated as follows: probability (rejecting mean (i) = mean (j) given difference = x).

A two-tailed significance level of 0.05 was used. The difference stated in the above probability statement was expressed as a percentage of a reported standard deviation. Thus, 5% increase was one standard deviation, and the square of this value was what was assumed to estimate the pooled variance estimate calculated in the analysis of variance. Six rats per treatment group provided us with a power of more than 0.80 at α = 0.05 to detect a difference in BMD of one standard deviation.

Data Analysis. For each age group (initial age of 5 months or 10 months), a 3-way randomized design (ovx, ovx + E2, and sham) was utilized. SigmaStat 3.5 (Systat Software Inc., San Jose, CA) was used to analyze the data and when a one-way ANOVA indicated any significant differences among the means, Tukey’s post hoc test was performed. Statistical significance was set at the p < 0.05 level for all analyses. Study was designed to detect the significant cooccurrence of obesity, osteoporosis, and sarcopenia and was terminated upon DXA measurements that provided significant changes in these body tissues. Therefore, the duration of ovarian hormone deficiency was different between the two age groups; three and half months for young animals and five months for older group. To avoid the impact of time differences in duration of ovarian hormone deficiency and estradiol exposure on body composition, the comparison was made among sham and ovx and sham and ovx + E2 in each age group only, using one-way ANOVA.

3. Results

3.1. Food Intake, Physical Activity, and Body and Organ Weights. Even though ovx rats were pair-fed with the mean food intake of sham animals, the final BWs of ovx rats in both age groups were significantly higher than sham rats (Table 1). E2 administration prevented the ovariectomy-induced weight gain. Success of the surgical procedure was evident by atrophy of the uterus that was prevented by E2. No significant differences were found between mean heart and liver weights (Table 1). Older ovx rats significantly decreased 24-hour voluntary wheel running activity by 57% compared with sham animals and younger ovx rats tended (p = 0.08) to have a lower activity (Figure 1).
Table 1: The effects of ovariectomy (ovx) and 17β-estradiol (ovx + E2) on food intake, body, and organ weight in rats with initial ages of five and ten months. Despite pair-feeding the animals, ovariectomy significantly increased body weight and caused atrophy of uterine tissue without any effects on heart or liver weights.

| Parameter            | Sham         | 5-month-old Ovx | Ovx + E2 | Sham         | 10-month-old Ovx | Ovx + E2 |
|----------------------|--------------|-----------------|----------|--------------|------------------|----------|
| Food intake (g/day)  | 16.38 ± 9.1  | 16.39 ± 9.8     | 16.05 ± 9.4 | 15.65 ± 9.1  | 15.68 ± 9.8      | 15.01 ± 9.4 |
| Body weight (g)      |              |                 |           |              |                  |          |
| Initial              | 294.00 ± 6.96| 293.33 ± 6.65   | 293.67 ± 4.99 | 369.40 ± 6.96 | 370.00 ± 6.65     | 361.98 ± 4.99 |
| Final                | 366.40 ± 9.8a| 400.40 ± 9.8b   | 350.33 ± 13.38a | 421.80 ± 9.8a | 474.00 ± 10.35b  | 404.00 ± 6.91a |
| Organ weight (mg)    |              |                 |           |              |                  |          |
| Uterus               | 0.618 ± 0.05a| 0.098 ± 0.01b   | 0.287 ± 0.03c | 0.733 ± 0.05A | 0.140 ± 0.02B    | 0.232 ± 0.01C |
| Liver                | 10.64 ± 0.653| 9.362 ± 0.236   | 8.750 ± 0.617 | 12.98 ± 1.33  | 13.22 ± 2.03      | 10.66 ± 0.06 |
| Heart                | 1.050 ± 0.057| 0.965 ± 0.0293  | 0.950 ± 0.029 | 1.186 ± 0.029 | 1.167 ± 0.035     | 1.125 ± 0.027 |

Values are means ± SEM. Values that do not share the same superscript letters in each age category are significantly (p < 0.05) different from each other (n = 6 per treatment group).

| Parameters                 | Sham         | 5-month-old Ovx | Ovx + E2 | Sham         | 10-month-old Ovx | Ovx + E2 |
|----------------------------|--------------|-----------------|----------|--------------|------------------|----------|
| Total fat mass (g/cm³)     |              |                 |           |              |                  |          |
| Baseline                   | 69.4 ± 6.5   | 70.5 ± 5.9      | 73.2 ± 5.5 | 102.6 ± 14.9 | 100.3 ± 12.8     | 101.3 ± 10.0 |
| Final                      | 172.0 ± 10.5a| 226.0 ± 8.7b    | 170.2 ± 13.2a | 218.6 ± 11.5A | 284.0 ± 7.5B     | 217.7 ± 7.7A |
| Total lean mass (g)        |              |                 |           |              |                  |          |
| Baseline                   | 204.6 ± 10.6 | 203.8 ± 7.5     | 203.0 ± 7.1 | 221.4 ± 9.3  | 231.2 ± 8.3      | 219.8 ± 6.6 |
| Final                      | 167.0 ± 11.0a| 146.2 ± 9.1b    | 160.2 ± 9.6a | 168.2 ± 10.5 | 152.2 ± 11.1     | 160.2 ± 4.6 |
| Total BMD (g/cm³)          |              |                 |           |              |                  |          |
| Baseline                   | 0.159 ± 0.0008 | 0.160 ± 0.004 | 0.161 ± 0.002 | 0.186 ± 0.007 | 0.187 ± 0.003     | 0.181 ± 0.003 |
| Final                      | 0.173 ± 0.003a | 0.158 ± 11.96b | 0.172 ± 0.004a | 0.181 ± 0.008A | 0.169 ± 0.002b    | 0.179 ± 0.006A |
| Total BMC (g)              |              |                 |           |              |                  |          |
| Baseline                   | 8.940 ± 0.108 | 8.800 ± 0.144  | 9.100 ± 0.224 | 11.460 ± 0.93 | 11.350 ± 0.19     | 10.517 ± 0.53 |
| Final                      | 11.54 ± 0.42 | 11.60 ± 0.004  | 11.18 ± 0.004 | 13.60 ± 0.80  | 13.73 ± 0.34      | 13.17 ± 0.38 |

Values are means ± SEM. Values that do not share the same superscript letters in each age category are significantly (p < 0.05) different from each other. BMD, bone mineral density; BMC, bone mineral content (n = 6 per treatment group).

3.2. Body Composition. The excess BW gain in ovx rats of both age groups was mainly due to a 30% increase of fat mass (p = 0.006 and p = 0.02, resp., for young and old animals) that was completely prevented by E2 (Table 2).

In both age groups ovariectomy significantly reduced whole body BMD, in comparison with sham animals, without affecting BMC due to the simultaneous increases in bone areas (Table 2). Furthermore, the whole body BMD was 9% lower in older animals, reflecting the impact of aging in addition to ovariectomy. E2 prevented these alterations in both age groups.

Ovariectomy induced a significant loss of tibial and vertebral BMD in both age groups which was more pronounced in older rats (22% and 16% loss, resp., for tibiae and vertebrae in older animals). The loss of BMC was observed in both tibiae and vertebrae in older ovx rats and only in vertebrae of younger ovx animals. E2 prevented the loss of BMD and BMC only in younger animals (Table 3).

3.3. Microcomputed Tomography (µCT) Analysis. Representative images of the 3D trabecular microstructures of proximal tibiae of the three groups in the older (initial age of 10 months) cohort are presented in Figure 2. Ovariectomy significantly decreased trabecular BV/TV in tibiae (73% and 86%, resp., in young and old rats) and lumbar (46% and 49%, resp., for young and old rats), compared with their corresponding sham animals (Figures 3(a) and 3(b)). E2 only prevented the vertebral trabecular bone loss in younger animals.

The mean proximal tibial values for Tb. N were significantly reduced in both age groups (65% and 73%, resp., in young and old rats) that were prevented by E2. Only older
Table 3: The effects of ovariectomy (ovx) and 17β-estradiol (ovx + E2) on bone mineral density and bone mineral content of the 4th lumbar and right tibia in rats with initial ages of five and ten months. The mean tibial and vertebral bone mineral density and bone mineral content of ovx rats were significantly lower in comparison with sham rats in both age groups and E2 administration prevented the bone loss.

| Parameters | 5-month-old | 10-month-old |
|------------|-------------|--------------|
|            | Sham | Ovx | Ovx + E2 | Sham | Ovx | Ovx + E2 |
| 4th lumbar |      |     |         |      |     |         |
| BMD (g/cm²) | 0.246 ± 0.005a | 0.195 ± 0.002b | 0.240 ± 0.005a | 0.266 ± 0.016A | 0.207 ± 0.004B | 0.230 ± 0.004C |
| BMC (g)    | 0.130 ± 0.007a | 0.089 ± 0.005b | 0.128 ± 0.006b | 0.162 ± 0.017A | 0.115 ± 0.003B | 0.127 ± 0.005C |
| Right tibia|      |     |         |      |     |         |
| BMD (g/cm²) | 0.211 ± 0.003a | 0.183 ± 0.004b | 0.209 ± 0.002b | 0.240 ± 0.009A | 0.204 ± 0.004B | 0.218 ± 0.004C |
| BMC (g)    | 0.314 ± 0.003 | 0.292 ± 0.007 | 0.309 ± 0.007 | 0.375 ± 0.002A | 0.331 ± 0.009B | 0.338 ± 0.006C |

Values are means ± SEM. Values that do not share the same superscript letters in each age category are significantly (p < 0.05) different from each other. BMD, bone mineral density; BMC, bone mineral content (n = 6 per treatment group).

Figure 2: 3D trabecular images representative of proximal right tibia of sham (a), ovariectomy (ovx) (b), and 17β-estradiol (ovx + E2) (c). The images were acquired using μCT (Methods). Ovariectomy decreased trabecular bone structure when compared to sham in rats from the cohort of initial age of ten months. This effect was prevented by E2 administration. Similar effects were observed in younger animals (n = 6 per treatment group).

Ovx rats experienced a significant loss (45%) of vertebral Tb. N (Figures 3(c) and 3(d)). Tb. Sp. significantly increased in both tibiae and vertebrae of the older ovx rats (74% and 46%, resp.) and tibiae of the younger ovx group; only the latter was prevented by E2 (Figures 3(e) and 3(f)).

Both ovx age groups experienced a reduced Tb. Th. that reached a significant level only in the tibiae of the older ovx animals which was not prevented by E2 (Figures 3(g) and 3(h)).

A significant reduction of Conn. D was observed in tibiae of both ovx age groups and vertebrae of the older animals. The latter was prevented by E2 (Figures 3(i) and 3(j)).

SMI, which quantifies the pattern of trabeculae as either more rod- or plate-like, was 1.69 and 0.572 in tibiae and vertebrae of younger sham rats, respectively (Figure 3(k)). SMI values for both bones increased in ovx rats; that is, SMI = 2.753 and 1.18 in tibiae and vertebrae, respectively, indicating a shift to less favorable rod-like trabecular bone. Similarly in older animals SMI values for tibiae and vertebrae were both increased compared to those of sham values, that is, 2.78 versus 1.49 and 1.07 versus 0.41 (Figure 3(l)). The higher SMI values in ovx rats indicated that ovariectomy made the remaining bone inferior. E2 prevented the vertebral increase in SMI (Figure 3(l)).

3.4. Muscle Mass and Ratios. Muscle mass was not significantly affected by ovariectomy. However, when SOL and GAS values were normalized to BW, mean GAS value in the younger ovx + E2 group tended (p = 0.09) to increase compared with that of sham group (Table 4).

In older ovx rats, normalized SOL value tended (p = 0.094) to decrease and GAS value was significantly lower than that of the sham and/or ovx + E2 groups. E2 prevented the loss of SOL and GAS by 50% and 100%, respectively. In both age groups the ratio of tibial BMC to combined GAS and SOL values of ovx group was significantly lower (12% and 21%, resp., for young and old animals) than that of sham and/or ovx + E2 groups which was prevented by estrogen (Table 4).

3.5. Blood Parameters. Ovariectomy significantly lowered serum E2 levels and increased B-ALP (28% and 26%, resp., for ovx young and old rats) and CTX (31% and 34%, resp., for ovx young and old animals) in both age groups. Although E2 administration in both age groups lowered B-ALP and CTX levels, they were higher than that of sham animals (Table 5).
Figure 3: Continued.
Figure 3: The effects of ovariectomy (ovx) and 17β-estradiol (ovx + E₂) on BV/TV, bone volume/total volume (a and b); Tb. N, trabecular number (c and d); Tb. Sp, trabecular separation (e and f); Tb. Th., trabecular thickness (g and h); Conn. D, connectivity density (i and j); SMI, structure model index (k and l) of right tibiae and 4th lumbar vertebrae in rats from the cohorts of initial ages of five (a, c, e, g, i, and k) and ten months (b, d, f, h, j, and l). Values are means ± SEM. Bars that do not share the same superscript letters are significantly (p < 0.05) different from each other. Small and large letters represent tibia and lumbar, respectively (n = 6 per treatment group). Ovariectomy significantly decreased tibia and lumbar trabecular BV/TV, bone volume/total volume, in both age groups that was only prevented by estrogen, in the vertebral bone of younger animals (a and b). In both age groups the mean proximal tibial values for Tb. N were significantly reduced following ovariectomy that was prevented by E₂ (c and d). Tb. Sp. significantly increased in both tibiae and vertebrae of the older ovx rats and tibiae of the younger ovx group; only the latter was prevented by E₂ (e and f). Reduced levels of Tb. Th. reached a significant level only in the tibiae of the older ovx animals which was not prevented by E₂ (g and h). Conn. D was reduced in tibiae of both ovx age groups and vertebrae of the older animals. The latter was prevented by estrogen (i and j). SMI values for both bones increased in both ovx age groups which was prevented by E₂ only in vertebral bones (l).

Table 4: The effects of ovariectomy (ovx) and 17β-estradiol (ovx + E₂) on muscle mass and normalized muscle mass in rats with initial ages of five and ten months. Ovariectomy did not affect the muscle mass but decreased ratio of tibial bone mineral content to combined muscle content in both age groups and lowered normalized values of gastrocnemius muscle to body weight in older rats that were prevented by E₂ administration.

| Parameters          | 5-month-old          | 10-month-old         |
|---------------------|----------------------|----------------------|
|                     | Sham                 | Ovx                  | Ovx + E₂ | Sham                 | Ovx                  | Ovx + E₂ |
| Muscle mass         |                       |                      |          |                       |                      |          |
| Gastrocnemius (g)   | 1.7814 ± 5.886       | 2.0763 ± 4.442       | 1.8828 ± 5.747 | 2.228 ± 1.09         | 2.242 ± 0.004       | 2.129 ± 0.054       |
| Soleus (mg)         | 135 ± 9.2            | 163 ± 9.1            | 139 ± 12 | 150 ± 7.0            | 151 ± 9.1           | 140 ± 5.1           |
| MM/BW (mg/g)        | 4.881 ± 0.0231       | 5.191 ± 0.0118       | 5.458 ± 0.0197 | 5.28 ± 0.005⁵       | 4.73 ± 0.011⁵       | 5.28 ± 0.015⁴       |
| Gastrocnemius (µg/mg) | 16.483 ± 0.596       | 13.042 ± 0.123³      | 14.872 ± 0.400⁵ | 15.728 ± 0.795³    | 13.879 ± 0.304³     | 14.541 ± 0.439³     |

Values are means ± SEM. Values that do not share the same superscript letters in each age category are significantly (p < 0.05) different from each other. MM, muscle mass; BW, body weight, BMC, right tibia bone mineral content; CMM, combined muscle mass (n = 6 per treatment group).
4. Discussion

Our data suggest that ovarian hormone deficiency underlies pathophysiologic obesity followed by osteoporosis that also extended to sarcopenia. Since pair-feeding the animals ruled out the confounding factor of energy intake, excess fat mass suggests a significant decrease in energy expenditure in both age groups. This was partially reflected by decreased 24-hour voluntary wheel running activity that was prevented by E₂. Estradiol administration prevented both ovariectomy-induced increase in fat mass and decrease in lean mass including bone mass. Therefore, these alterations in body composition and in physical activity can be attributed to estradiol, the main ovarian hormone. Advancing age in these younger age ovarian deficient animal models negatively affects body composition, years before traditional diagnosis of these age-related diseases. We also observed a site specific, age independent protective effect of E₂ on muscle mass. Moreover, our data suggest an anticatabolic role for E₂ in younger rats, reflected by higher ratio of normalized mean GAS value in the ovx + E₂ group compared with that of corresponding mean sham value.

Ovarian hormones may have a direct role on adiposity by increasing hormone-sensitive lipase activity, lipolytic effects of epinephrine, and beta oxidation of fatty acids [6–8]. In addition to the direct effect of ovarian hormone on adipose tissue, it may indirectly affect adiposity via regulation of food intake and energy expenditure through the hypothalamus, the key regulator of food intake and energy homeostasis in the brain [5, 9]. In the present study, BW was greater for ovx animals in both age groups despite similar food consumption compared with those of sham-operated rats. The observed increase in BW was associated with increased fat mass suggesting a shift in energy metabolism. Reduced voluntary physical activity may, in part, explain these unfavorable ovariectomy-induced body compositional changes. Similar results have been reported from ovx animals, displaying an increase in food consumption and a decrease in voluntary physical activity [20, 21]. Consistent with animal findings, human studies have also demonstrated that women, particularly a few years after the onset of menopause, gain weight because of increased fat mass and that postmenopausal women have greater appetite with less desire for physical activity [22].

In addition to the interrelationship between E₂ and adiposity, it is known to be positively associated with bone mass. Despite the commonly held belief that obesity is beneficial to maintain bone health [23], recent findings show an inverse relationship between fat mass and bone mass in both humans and laboratory animals [3, 4]. In the present study, our obese ovx rats lost bone mass and quality. We observed a significant loss of BMD and BMC in whole body and regional bones in the ovx groups, and this loss was more pronounced in our older ovx animals. The microarchitectural properties of the trabecular bone in both tibiae and lumbar vertebrae, in contrast to the effects of ovariectomy and ovx + E₂ with those of sham values in each age group, clearly demonstrate the importance of ovarian hormones. Our results also confirmed that ovariectomy caused loss of tibial BV/TV, Tb. N, and Conn. D and increased Tb. Sp. although the degree of loss was greater in older rats than in younger animals. These findings indicate that advancing age, aside from other factors, such as ovarian hormone deficiency that deleteriously affect bone microstructure, can be an independent factor affecting bone loss. This could be related in part to age-dependent changes in bone mesenchymal stem cells [24] and the role of estrogen in directing their differentiation into either adipocytes or osteoblasts [25]. Our results are consistent with findings of other investigators reporting that in addition to BMD bone microarchitecture deteriorates because of ovarian hormone deficiency in both women and in ovx animals [26, 27].

Unlike the observations made in postmenopausal women and osteoporotic men [28] who often experience increases in trabecular thickness as a result of reduced trabeculae, our results showed a decrease in Tb. Th. following ovariectomy. This, in part, can be explained by the morphological differences between the two species in bone and in muscle structures. Because of their structural physiology, rats do not experience fractures even when severe bone loss is evident [29]. Alternatively, the skeletal system in humans compensates for the loss of trabeculae through an increase in the thickness of the remaining trabeculae [30]. Although this may postpone fracture, continued bone loss in humans eventually leads to fracture because of increased stress associated with thinning and perforation of trabeculae [30]. In the present study, μCT analysis indicated that E₂ treatment partially prevented the loss of trabecular structures, findings which concur with observations by Lark et al. [31, 32]. Administration of E₂ also had a more pronounced modulating effect in younger rats than in older rats.

In addition to the structural parameters, other morphological parameters, such as SMI, reflect bone quality and strength. The SMI value is based on surface density and thickness of a 3-dimensional structure. Its value is multiplied
by a factor to yield more practical numbers, 0 for ideal plates, 3 for ideal rods, and 4 for true spheres [33]. A plate-like structure is generally stronger than a rod-like structure [33]. The SMI values in both age categories were higher in ovx rats compared to corresponding sham animals, indicating that ovarian hormone deficiency not only causes bone loss, but also, at the same time, decreases the quality of the remaining bone.

In humans and rodents, both estrogen receptors (ERs), ERα and ERβ, are expressed in skeletal muscle, making it a target tissue of estrogen action [10]. Although a number of studies support a link between muscle mass and estrogen [34, 35], not all results from human and animal studies are in agreement about the relationship between estrogen and skeletal muscle. Results of human studies are inconsistent because of the variety of study designs (e.g., cross-sectional versus longitudinal) and because of age and gender differences of the samples examined [34]. Other contributing factors adding to these inconsistencies among animal studies include variations in animal models used, the duration of experiments, and the age of the animals [13, 14]. In the present study, we were able to demonstrate the coexistence of obesity with sarcopenia in the older osteopenic ovx rats. Our findings are consistent with several reports by other investigators [13, 14] which have reported that ovarian hormone deficiency delays recovery of the skeletal muscle mass from disuse-induced muscle atrophy in rats. ERα interacts with nuclear troponin I in fast skeletal muscle [36]. Interestingly, nuclear localization of troponin I has also been identified in cardiac muscle [37] and could be associated with some forms of cardiomyopathy that alter myocyte size [38]. In addition, nuclear localization of troponin T, which is a binding partner of troponin I in striated muscles, has been shown to vary with age, and this may be associated with some aspects of sarcopenia [39–41]. Interestingly, we observed a greater response to E2 manipulation in GAS skeletal muscle compared with SOL that may in part be explained by higher proportion of ERα on fast-twitch muscle fibers. Also, in cross-sectional studies, a positive relationship between muscle mass and plasma levels of estrogen, estrone, and estradiol in women has been reported suggesting a faster decline of muscle mass in premenopausal women [35]. Furthermore, consistent with Frost’s hypothesis and data from postmenopausal women [42, 43], we observed a significant decline in the ratio of tibial BMC to skeletal muscle mass in our ovx rats in both age groups, an effect that was prevented by E2. These findings suggest that E2 may lower the required load to prevent bone loss or promote bone formation.

Consistent with available literature we observed a site specific protective effect of E2 on skeletal muscle [43]. Our estrogen administered rats maintained muscle weights, irrespective of age. Furthermore, our findings revealed an apparent anticitabolic effect of E2 in five-month-old animals, as the mean normalized GAS and SOL weights of E2 treated rats were higher than both sham and ovx groups. The potential anticitabolic effect of E2 on skeletal muscle has been reported using young ovx rats and human studies with younger subjects; however, there may be less of an effect of E2 with advancing age, but the strength of evidence to support this contention is minimal.

Ovx rat is the most commonly used model demonstrating bone loss [19]. Similar to menopause, the ovx rats experience increased rates of bone resorption and bone formation with the rate of resorption exceeding that of formation [19] which results in a net loss of bone mass. In our study, the bone resorption marker CTX was significantly elevated in both obese ovx rats and exceeded that of bone formation marker B-ALP in these animals compared to corresponding sham rats of both age groups. E2 deficiency in the ovx rat model appears to be the most appropriate method available for modeling excess resorption not accompanied by formation deficit [19]. In addition to loss of bone mass, ovx rats increase fat mass along with a gradual decline in muscle mass. Therefore, the ovx rat could be used as an experimental model to conduct obesity translational research without the confounding effects of diet or genetic background.

Our findings suggested that the cooccurrence of obesity and sarcopenia along with osteoporosis may be found in ovarian hormone deficient women as a result of several factors which work together and exacerbate mobility disability. First, the gradual reduction in female sex hormones by advancing age can affect energy intake and expenditure and potentially contribute to added fat accumulation and obesity. Low levels of ovarian hormones are linked to decreased spontaneous physical activity and to decreased energy expenditure, leading to an increase in fat mass even without additional energy intake. Second, excess adiposity may impair bone and muscle mass and function on a physiological basis through certain mechanisms affected by systemic inflammation and impaired metabolic function. Third, the excess weight, along with bone and muscle loss, may result in an impaired functionality that accounts for a higher rate of obesity and obesity related medical complications. All of these factors may contribute to frailty and to increased risk of mortality in women with low levels of ovarian hormones.

5. Conclusion

In summary, using five- and ten-month-old ovx rats (initial age of five or ten months) enabled us to disentangle the effect of ovarian hormone deficiency from the complex multifactorial process of chronological aging in the female body while controlling for energy intake and measuring physical inactivity. Our findings in these two age cohorts ovx SD rats suggested that removal of ovaries alters BC similar to what can be manifested as osteosarcopenic obesity in postmenopausal women. While previous studies have investigated these age-related disease conditions in isolation, in older animals that mimic the same age as of menopausal women, to the best of our knowledge, the cooccurrence of all of these three conditions has not yet been examined. To understand the mechanistic relationship between these diseases, our study demonstrates the utility of ovx rat as a proper model for future translational research. Future studies are needed to examine the effects of ovarian hormone deficiency on changes that occur in energy metabolism in fat and fat-free mass and the roles that E2 plays in promoting
homeostasis and the mechanistic crossroads that lead to divergent outcomes following $E_2$ exposure. Also, the related clinical dimensions and interactions of obesity, sarcopenia, and osteoporosis need to be investigated.

Conflicts of Interest

Zahra Ezzat-Zadeh, Jeong-Su Kim, P. Bryant Chase, and Bahram H. Arjmandi have no conflicts of interest.

References

[1] J. A. Batis, T. A. Mackenzie, F. Lopez-Jimenez, and S. J. Bartels, "Sarcopenia, sarcopenic obesity, and functional impairments in older adults: National Health and Nutrition Examination Surveys 1999–2004," *Nutrition Research*, vol. 35, no. 12, pp. 1031–1039, 2015.

[2] E. M. Lewiecki, J. P. Bilezikian, L. Bonewald et al., "Osteoporosis update: proceedings of the 2013 santa fe bone symposium," *Journal of Clinical Densitometry*, vol. 17, no. 3, pp. 330–343, 2014.

[3] S. Migliaccio, E. A. Greco, R. Fornari, L. M. Donini, L. Di Luigi, and A. Lenzi, "Skeletal alterations in women affected by obesity," *Aging Clinical and Experimental Research*, vol. 25, supplement 1, pp. S35–S37, 2013.

[4] G. V. Halade, M. M. Rahman, P. J. Williams, and G. Fernandes, "High fat diet-induced animal model of age-associated obesity and osteoporosis," *The Journal of Nutritional Biochemistry*, vol. 21, no. 12, pp. 1162–1169, 2010.

[5] P. S. Cooke and A. Naaz, "Role of estrogen in adipocyte development and function," *Experimental Biology and Medicine*, vol. 229, pp. 1127–1135, 2004.

[6] S. B. Pedersen, K. Kristensen, P. A. Hermann, J. A. Katenzelbogen, and B. Richelsen, "Estrogen controls lipolysis by up-regulating α2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor α. Implications for the female fat distribution," *Journal of Clinical Endocrinology and Metabolism*, vol. 89, no. 4, pp. 1869–1878, 2004.

[7] S. L. Palin, P. G. McTernan, L. A. Anderson, D. W. Sturdee, A. H. Barnett, and S. Kumar, "17β-Estradiol and anti-estrogenICI:compound182,780regulateexpressionoflipoproteinlipaseandhormone-sensitive lipase in isolated subcutaneous abdominal adipocytes," *Metabolism: Clinical and Experimental*, vol. 52, no. 4, pp. 383–388, 2003.

[8] M. L. Misso, Y. Murata, W. C. Boon, M. E. Jones, K. L. Britt, and E. R. Simpson, "Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse," *Endocrinology*, vol. 144, no. 4, pp. 1474–1480, 2003.

[9] R. Meli, M. Pacilio, G. M. Rao et al., "Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats," *Endocrinology*, vol. 145, no. 7, pp. 3115–3121, 2004.

[10] A. Wilk, M. Ekman, O. Johansson, E. Jansson, and M. Esbjörnsson, "Expression of both oestrogen receptor alpha and beta in human skeletal muscle tissue," *Histochemistry and Cell Biology*, vol. 131, no. 2, pp. 181–189, 2009.

[11] D. J. Glass, "Signalling pathways that mediate skeletal muscle hypertrophy and atrophy," *Nature Cell Biology*, vol. 5, no. 2, pp. 87–90, 2003.

[12] A. L. Moran, G. L. Warren, and D. A. Lowe, "Removal of ovarian hormones from mature mice detrimentally affects muscle contractile function and myosin structural distribution," *Journal of Applied Physiology*, vol. 100, no. 2, pp. 548–554, 2006.

[13] J. M. McClung, J. M. Davis, M. A. Wilson, E. C. Goldsmith, and J. A. Carson, "Estrogen status and skeletal muscle recovery from disuse atrophy," *Journal of Applied Physiology*, vol. 100, no. 6, pp. 2012–2023, 2006.

[14] A. M. Moran, S. A. Nelson, R. M. Landisch, G. L. Warren, and D. A. Lowe, "Estradiol replacement reverses ovariectomy-induced muscle contractile and myosin dysfunction in mature female mice," *Journal of Applied Physiology*, vol. 102, no. 4, pp. 1387–1393, 2007.

[15] M. Brown, A. Foley, and J. A. Ferreria, "Ovariectomy, hindlimb unweighting, and recovery effects on skeletal muscle in adult rats," *Aviation Space and Environmental Medicine*, vol. 76, no. 11, pp. 1012–1018, 2005.

[16] D. L. Enns and P. M. Tiidus, "The influence of estrogen on skeletal muscle: sex matters," *Sports Medicine*, vol. 40, no. 1, pp. 41–58, 2010.

[17] J. J. Sciote, M. J. Horton, Y. Zyman, and G. Pascoe, "Differential effects of diminished oestrogen and androgen levels on development of skeletal muscle fibres in hypogonadal mice," *Acta Physiologica Scandinavica*, vol. 172, no. 3, pp. 179–187, 2001.

[18] M. Kassem, "Cellular and molecular effects of growth hormone and estrogen on human bone cells," *APMIS*, vol. 105, supplement 71, pp. 7–30, 1997.

[19] D. N. Kalu, "The ovariectomized rat model of postmenopausal bone loss," *Bone and Mineral*, vol. 15, no. 3, pp. 175–191, 1991.

[20] E. J. Roy and G. N. Wade, "Role of food intake in estradiol-induced body weight changes in female rats," *Hormones and Behavior*, vol. 8, no. 3, pp. 265–274, 1977.

[21] H. Fonseca, S. K. Powers, D. Gonales, A. Santos, M. P. Mota, and J. A. Duarte, "Physical inactivity is a major contributor to ovariectomy-induced sarcopenia," *International Journal of Sports Medicine*, vol. 33, no. 4, pp. 268–278, 2012.

[22] J. C. Lovejoy, C. M. Champagne, L. de Jonge, H. Xie, and S. R. Smith, "Increased visceral fat and decreased energy expenditure during the menopausal transition," *International Journal of Obesity*, vol. 32, no. 6, pp. 949–958, 2008.

[23] I. R. Reid, R. Ames, M. C. Evans et al., "Determinants of total body and regional bone mineral density in normal postmenopausal women—a key role for fat mass," *The Journal of Clinical Endocrinology & Metabolism*, vol. 75, no. 1, pp. 45–51, 1992.

[24] F. Z. Asumda and P. B. Chase, "Age-related changes in rat bone-marrow mesenchymal stem cell plasticity," *BMC Cell Biology*, vol. 12, article 44, 2011.

[25] J.-W. Zhao, Z.-L. Gao, H. Mei, Y.-L. Li, and Y. Wang, "Differentiation of human mesenchymal stem cells: the potential mechanism for estrogen-induced preferential osteoblast versus adipocyte differentiation," *American Journal of the Medical Sciences*, vol. 341, no. 6, pp. 460–468, 2011.

[26] M. D. Walker, X. S. Liu, B. Zhou et al., "Premenopausal and postmenopausal differences in bone microstructure and mechanical competence in Chinese-American and white women," *Journal of Bone and Mineral Research*, vol. 28, no. 6, pp. 1308–1318, 2013.

[27] Å. Tivesten, S. Movéras-Skrsic, A. Chagin et al., "Additive protective effects of estrogen and androgen treatment on trabecular bone in ovariectomized rats," *Journal of Bone and Mineral Research*, vol. 19, no. 11, pp. 1833–1839, 2004.

[28] J. S. Thomsen, M. V. Jensen, A. S. Nikkelsen, E. N. Ebbesen, and A. Brüel, "Age-related changes in vertebral and iliac crest 3D bone microstructure—differences and similarities," *Osteoporosis International*, vol. 26, no. 1, pp. 219–228, 2014.
[29] T. Mawatari, H. Miura, H. Higaki et al., "Quantitative analysis of three-dimensional complexity and connectivity changes in trabecular microarchitecture in relation to aging, menopause, and inflammation," Journal of Orthopaedic Science, vol. 4, no. 6, pp. 431–438, 1999.

[30] V. Pattijn, T. Van Cleynenbreugel, J. V. Sloten, R. Van Audekercke, G. Van Der Perre, and M. Wevers, "Structural and radiological parameters for the nondestructive characterization of trabecular bone," Annals of Biomedical Engineering, vol. 29, no. 12, pp. 1064–1073, 2001.

[31] M. W. Lark, G. B. Stroup, R. A. Dodds et al., "Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat," Journal of Bone and Mineral Research, vol. 16, no. 2, pp. 319–327, 2001.

[32] M. W. Lark, G. B. Stroup, I. E. James et al., "A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat," Bone, vol. 30, no. 5, pp. 746–753, 2002.

[33] T. Hildebrand and P. Rueggsegger, "Quantification of bone microarchitecture with the structure model index," Computer Methods in Biomechanics and Biomedical Engineering, vol. 1, no. 1, pp. 15–23, 1997.

[34] V. Messier, R. Rabasa-Lhoret, S. Barbat-Artigas, B. Elisha, A. D. Karelis, and M. Aubertin-Leheudre, "Menopause and sarcopenia: a potential role for sex hormones," Maturitas, vol. 68, no. 4, pp. 331–336, 2011.

[35] Y. Li, B. Chen, J. Chen, G. Lou, S. Chen, and D. Zhou, "Fast skeletal muscle troponin I is a co-activator of estrogen receptor-related receptor α," Biochemical and Biophysical Research Communications, vol. 369, no. 4, pp. 1034–1040, 2008.

[36] Z. Asumda and P. B. Chase, "Nuclear cardiac troponin and tropomyosin are expressed early in cardiac differentiation of rat mesenchymal stem cells," Differentiation, vol. 83, no. 3, pp. 106–115, 2012.

[37] P. B. Chase, M. P. Szczypinski, and E. P. Soto, "Nuclear tropomyosin and troponin in striated muscle: new roles in a new locale?" Journal of Muscle Research and Cell Motility, vol. 34, no. 3–4, pp. 275–284, 2013.

[38] T. Zhang, A. Birbrair, Z.-M. Wang, J. Taylor, M. L. Messi, and O. Delbono, "Troponin T nuclear localization and its role in aging skeletal muscle," Age, vol. 35, no. 2, pp. 353–370, 2013.

[39] T. Zhang, A. S. Pereyra, Z.-M. Wang et al., "Calpain inhibition rescues troponin T3 fragmentation, increases Cav1.1, and enhances skeletal muscle force in aging sedentary mice," Aging Cell, vol. 15, no. 3, pp. 488–498, 2016.

[40] J. R. Pinto, J. Muller-Delp, and P. B. Chase, "Will you still need me (Ca2+, TRPC, and DHPR), will you still cleave me (calpain), when I’m 64?" Aging Cell, vol. 16, no. 2, pp. 202–204, 2017.

[41] H. M. Frost, "The role of changes in mechanical usage set points in the pathogenesis of osteoporosis," Journal of Bone and Mineral Research, vol. 7, no. 3, pp. 253–261, 1992.

[42] W. M. Kohrt, D. B. Sneed, E. Slatopolsky, and S. J. Birge Jr., "Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women," Journal of Bone and Mineral Research, vol. 10, no. 9, pp. 1303–1311, 1995.